Shanghai Fosun Pharmaceutical (600196) Q3 2024 earnings summary

Executive summary

• Revenue for the first three quarters of 2024 reached RMB 30.912 billion, up 5.74% year-over-year; Q3 revenue was RMB 10.45 billion, up 12.3% year-over-year.

• Excluding COVID-related products, revenue grew 5.74% year-over-year; innovative drug revenue showed steady growth.

• Net profit attributable to shareholders was RMB 2.011 billion for the first nine months; Q3 net profit was RMB 785.84 million, up 55.43% year-over-year.

• Net profit excluding non-recurring items rose 24.58% year-over-year; Q3 net profit excluding non-recurring items was RMB 582.17 million, up 474.77%.

• R&D expenses were RMB 2.648 billion, down 16.07% year-over-year, with a focus on pipeline optimization and efficient project management.

Financial highlights

• Gross profit for the first three quarters was RMB 15.022 billion, with a gross margin of 48.6%, unchanged year-over-year.

• Sales expenses decreased to RMB 6.592 billion, with the sales expense ratio dropping to 21.3% from 23.5% year-over-year.

• R&D expense ratio fell to 8.6% from 10.3% year-over-year, reflecting more focused investment.

• Financial expenses rose to RMB 855 million due to USD interest rate hikes and changes in debt scale.

• Operating cash flow for the first nine months was RMB 2.99 billion, up 21.33% year-over-year.

Outlook and guidance

• Continued focus on innovative drug development, R&D, and international expansion, with new product launches and regulatory approvals expected.

• Ongoing optimization of supply chain, asset, and financial structure to support cash flow and profitability.

• Expansion of direct sales channels in medical aesthetics and global markets to enhance margins.